|Bid||7.35 x 0|
|Ask||7.90 x 0|
|Day's range||7.60 - 7.60|
|52-week range||6.15 - 13.80|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Evolus, Inc. (EOLS) delivered earnings and revenue surprises of -14.29% and 0.39%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
To get a sense of who is truly in control of Evolus, Inc. ( NASDAQ:EOLS ), it is important to understand the ownership...
Shares of Evolus (NASDAQ: EOLS) were up by 27.1% for the week as of Friday afternoon, according to data provided by S&P Global Market Intelligence. The medical aesthetics company specializes in using neurotoxins as aesthetic therapies. The company said in its announcement that it expected fourth-quarter revenue of $43.6 million, up 26% year over year, and full-year revenue of $148.6 million, up 49% over 2021.